Select a medication above to begin.
Multihance
gadobenate dimeglumine
Black Box Warnings .
Risk with Inadvertent Intrathecal Administration
not approved for intrathecal use; intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, seizures
Nephrogenic Systemic Fibrosis
may result in fatal or debilitating fibrosis affecting skin, muscle, internal organs; avoid gadolinium-based contrast agents (GBCAs) in patients with impaired elimination of drugs, unless diagnostic info is essential and not available with non-contrasted MRI or other modalities; highest risk in patients with eGFR <30 or acute kidney injury; screen patients for acute kidney injury or other conditions that may reduce renal function; estimate GFR if patients at risk for chronically reduced renal function, including patients >60 yo and patients with HTN or diabetes; do not exceed recommended dose, allow sufficient time for drug elimination before re-administering in highest-risk patients; report any diagnosis of nephrogenic systemic fibrosis to Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088
Adult Dosing .
Dosage forms: INJ
magnetic resonance imaging, CNS
- [0.2 mL/kg/dose IV x1]
magnetic resonance angiography
- [0.2 mL/kg/dose IV x1]
- Info: for patients with known or suspected renal or aorto-ilio-femoral occlusive vascular disease
renal dosing
- [not defined]
- renal impairment: not defined
- HD: not defined, on dialysis days consider administering right before dialysis; PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
magnetic resonance imaging, CNS
- [<2 yo]
- Dose: 0.1-0.2 mL/kg/dose IV x1
- [2 yo and older]
- Dose: 0.2 mL/kg/dose IV x1
renal dosing
- [not defined]
- renal impairment: not defined
- HD: not defined, on dialysis days consider administering right before dialysis; PD: not defined
hepatic dosing
- [not defined]